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S_y The expron oftumour nerosis factor a (TNF-a) and its two distiwt receptors, TNF-R p55 and
TNF-R p75, was asessed by immunocytochemistry in 28 pnmary brast cancer and three reducton mammo-
pla spemens ('normal' breast tissue). Expression of TNF-a or TNF-R p75 was not detectable in normal
breast tssue or in non-maignant breas tissue adjacent to the tumours. By contra, TNF-R p55 was
expresad by occaional strnal cells in normal tssue. TNF-£ was expressed focally in 50'!. of the tumours
stdied, being largy localised to macrophalke cel in the stroma. TNF-R p55 was expressed by a
population of somnal cells in all the tumours eamined, and a varying proporton of neoplastic cels in 75%
of tes tissues. TNF-R p75 was detected in about 70V/. of the tumours, im unoractivity being confined
mainly to cel in the stroma. In this peimary stUdY there was no assoaon etwn the above cytokine
parameters and such measures of tumour biolgy as lymph node status, tumour grade, prolifeai activity or
degree of angogesis. However, thlrc was a correlaion between the exression of TNF-R p55 by blood
vessels and the number of leucocytes present.
Lymphocytes and macrophages represent a potential source
of the cytokine TNF-x within the tumour microenvironment.
Indeed, lymphocytes (CD4+, CD8+ cells) isolated from
breast cancer biopsies secrete TNF-x in vitro (Rubbert et at.,
1991), and the in situ production of TNF-z mRNA by cells
in malignant breast tumours has recently been demonstrated
(Miles et al., 1992).
TNF-a may be directly cytotoxic or cytostatic for tumour
cells or help both to recruit infiltrating cells to the tumour
site and to stimulate their tumoricidal activity (reviewed by
Balkwill, 1991). It may also induce haemorrhagic necrosis
within tumours by its activity on endothelial cells (Schuger et
al., 1989). Alternatively, the protumour effects of this
cytokine include promotion of angiogenesis at low doses
(Fajardo et al., 1992) and stimulation of the metastatic
potential ofovarian carcinoma cells in rodent tumour models
(Malik et al., 1990). However, the multfaceted role(s) of this
cytokine within solid tumours is largely unknown. Similarly,
the cellular targets ofTNF-1 in these tumours have yet to be
fullly identified.
In this preliminary study, the cellular distribution of TNF-
a and its two distinct TNF receptors (TNF-R p55 and p75)
was investigated by immunohistochemistry on frozen sections
of humnn breast cancer biopsies. To assess the possible con-
tribution of TNF-a to the activity of breast cancer cells in
situ, the expression of the above cytokine parameters was
correlated with: (i) proliferative activity, (ii) neovascularisa-
tion, (iii) degree of metastasis (lymph node status), (iv)
tumour grade and (v) degree of lymphoid infiltration.
Materland meth.&
Patients and tismes
Twenty-eght sporadic breast cancrs were randomly selected
from the departmental frozen tumour bank. The mean age of
patiets was 60 years. Four of the 28 patients had
premenopausal disease. The tumours i ed 23 ductal,
three mixed ductal/lobular cancers, one lobular and one
medullary canmcer. In ten tumours there was no lymph node
involvement at presentation, and 18 were axillary lymph
node positive. Three reduction mammoplasty specimens were
also examined. Surgically removed tissues were snap frozen,
stored in liquid nitrogen and cryostat sections (5-8 JLm) cut
for immunohistochemistry.
Immunohistochemistry
The antibodies used in the study are listed in Table I. Cryo-
stat sections were prencubated with normal rabbit serum
(undiluted), then with the primary monoclonal antibodies
diluted in Tris-buffered saline/10% normal human serum
(TBS/NHS) for 30 min. After washing in TBS, the sections
were incubated with rabbit anti-mouse Ig (1:25 in TBS/NHS)
for 30 mimi and washed in TBS. This was followed by
incubation with mouse alkal phosphatase-anti-alkaline
phosphatase (APAAP) complex (1:50 in TBS) for 30min.
The reaction was enhanced in each case by repeatng the last
two incubations for 10min each. Fast red was used as the
chromogen, and sections were counterstained with haema-
toxylin.
The expression of TNF-x and TNF receptors p55 and p75
was asessed separately on 'stromal cells' (i.e. fibroblasts and
lipocytes), mononuclear inflammatory cells infiltrating the
tumour, neoplastc cells (both invasive and in situ com-
ponents), and vascular endothelial cells over the entire sec-
tion. Antigen expression was assssed semiquantitatively
using the following grading scale: +, immunoreactivity in
less than 10% of the cell population; + +, immunoreactivity
in 10-50% of the population; + + +, immunoreactivity in
more than 50% of the population. To estimate neovas-
culrisation the number of CD31-positive capillaries with
apparent hmen was counted at five high-power fields (HPFs)
within the most densely vasuLaised area of the section
(Horak et a!., 1992) and scored as follows: +, fewer than five
vessels per average HPF; + +, 5-10 vessels per average
HPF; + + +, more than ten vessls per average HPF. The
expression of CD45 (leucocyte common antigen, LCA) was
over the entire section, while Ki67 expression was
only estmated over the neoplastic compartment. Both
antibodies were scored as follows: +, isolated single cells;
+ +, groups ofisolated ce+ls; + + +, moderate diffuse stain-
ing.
Negative controls for the primary antibodies used included
substitution by corresponding concentrations of mouse IgGI
or IgG2 as appropriate. The specificity of the signal obtained
using the TNF-a antibodies utr-l and htr-9 was tested by
preincubation of sections with excess recombinant human
TNF-a (Vince et al., 1993). Substantial reduction in staining
by both antibodies was achieved in the presence of I mg ml-
TNF-a.
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Table I Primary monoclonal antibodies used in this study
Antibody Antigen Source Reference
utr-l TNF-R p75 M. Brockhaus, Brockhaus et al. (1990)
Genzyme p80 TNF-R p75 Genzyme,
Cambridge, MA, USA
htr-9 TNF-R p55 M. Brockhaus, Ryffel et al. (1991)
Genzyme p60 TNF-R p55 Genzyme,
Cambridge, MA, USA
6 35 TNF-x A. Meager, Seralab, Meager et al. (1987)
MAS 485 TNF-a Crawley Down, UK
Ki-67 Proliferation-associated Dako, High Wycombe, Gerdes et al. (1982)
nuclear antigen UK
Anti-CD31 Platelet/endothelial Dako, High Wycombe, Kuzu et al. (1992)
cell adhesion molecule UK
Anti-CD45 Leucocyte common antigen Dako, High Wycombe, Schwinzer (1989)
UK
Table II Expression of TNF-a and its receptors in various tissue components of human
breast cancer
TNF receptor p55 TNF receptor p75 TNF
Normal NVeoplastic Stromal Vascular Stromal Vascular Stromal
2- 7- 5- 8- 10- 14-
9+ 3+ 15+ 20+ 16+ 14+
8++ 21 ++ 6++ I ++
6+++ 4+++ 4+++ 2+++ 1+++
20 ND
Monoclonal antibodies htr-9, utr-I and 6/35 were used to assess the expression of TNF-R
p55, TNF-R p75 and TNF-i, respectively, in human breast cancer biopsies. The number of
cases positive (+) or negative (-) for each parameter is indicated. The expression was
quantified (+ to +++) as described in Materials and methods (ND, normal tissue not
detected). TNF-R p75 and TNF-x expression was not detected in any normal or neoplastic
epithelial cells. In addition, TNF-a expression was also missing from vascular endothelial
cells.
For statistical analysis contingency tables and the x2 test
were used.
Results
The results are summarised in Table H and illustrated in
Figure la-f.
TNF-a expression
Although 50% of tumours showed some positive reaction
with TNF-a antibody 6/35, this was only detectable in a
small minority (<1%) of cells in the stroma with
macrophage-like morphology (Figure la). No normal or
neoplastic mammary epithelial cells demonstrated immuno-
reactivity for this cytokine. No staining for TNF-z was
detected in any of the 'normal' breast tissues studied. The
expression of TNF-x did not correlate with that of either
form of TNF receptor, or with the degree of leucocyte
infiltration, neoplastic proliferation, angiogenic activity,
lymph node involvement or tumour grade. Similar results to
the above were obtained with the anti-TNF-x monoclonal
MAS-485 (not shown).
Expression ofTNF-receptor p55
Stromal cells in all 28 tumours showed immunoreactivity
with monoclonal antibody htr-9. The proportion of
immunoreactive cells in individual breast cancers varied from
10% to 50% of the total stromal cell population. The signal
was often detected in elongate, fibroblast-like cells (Figure
lb). A subpopulation of mononuclear cells (10%) within
nests of infiltrating leucocytes were also positive for the
TNF-R p55 (Figure lc). In the majority of cases (82%) the
microvasculature also expressed this receptor (Figure ld).
However, not all capillary endothelial cells identified by
CD31 expression were positive for TNF-R p55. No associa-
tion between endothehal immunoreactivity and degree of
angiogenesis, as assessed by the number of blood vessels
present, was observed. Similarly, no association between
endothelial staining and lymph node metastasis or the extent
of intratumour necrosis was detected. However, a significant
correlation (X = 15.48, P = 0.02) between the expression of
TNF-R p55 by blood vessels and the amount of leucocyte
infiltration (LCA-positive cells) present in the tumour was
noted. Normal breast epithelial structures adjacent to tumour
was present in eight cases. In six of these, ductal epithelial
cells showed cytoplasmic immunoreactivity (data not shown).
In the other two cases the same structures were negative.
Sporadic, elongated fibroblast-like cells from reduction mam-
moplasty also showed immunoreactivity with htr-9 (not
shown).
In 75% of the tumours (one mixed, one medullary and 19
ductal cancers) neoplastic cells of both in situ and invasive
components expressed TNF-R p55 (Figure le). The propor-
tion of immunoreactive tumour cells in individual cases
varied from 10% to 70% of the total neoplastic population.
The neoplastic cells of one mixed, one lobular and five ductal
carcinomas were negative for TNF-R p55. No association
between the TNF receptor status of tumour cells and intra-
tumour necrosis or proliferative activity of neoplastic cells
was observed. Anti-TNF receptor p60 (Genzyme) produced a
virtually identical cellular staining pattern as htr-9 on
tumours.
Expression of TNF receptorp75
Approximately 70% of the tumours expressed TNF-R p75 in
sporadic fibroblast-like cells in the stroma, in endothelial cellsTNF-a AND TNF RECEPTORS IN BREAST CANCER 291
Figwe 1 Expression of TNF-a and its receptors in breast carcinoma. Frozen sections were stained with antibodies 6/35 a, htr-9 b-e, and utr-l f, and counterstained with haematoxylin. Positive cells are indicated by the red staining in the cytoplasm. a, illustrates sporadic TNF-a-producing cells in the microenvironment of neoplastic ceUs. b, demonstrates that some fibroblast-like cells in the stroma and neoplastic cells of in situ lesions express TNF-R p55. c-e, demonstrate that some leucocytes, capilary endothelial cells and infiltrating neoplastic cells, also express this receptor. f, illustrates that some of the tunour-infiltrating leucocytes also express TNF-R p75.
and in cells within nests of infiltrating lymphoid cells (Figure
If). No epithelial cells were immunoreactive with this
antibody. No association between the expression of TNF-R
p75 and any of the above biological parameters of the
tumours was detected. Normal mammary tissue showed no
inmunoreactivity with utr-i.
Although the number of tissues used in this study was
relatively small, our preliminary observations suggest that
expression of TNF and its receptor is up-regulated in the
majority of breast carcinomas when compared with 'normal'
breast tissue. However, it should be noted that the latter
group comprised non-malignant breast tissue adjacent to the
tumours and reduction mammoplasty samples, neither of
which may accurately represent normal breast tissue.
That TNF-x immunoreactivity was confined to sporadic, macrophage-like cells in the stroma of breast tumours
accords well with previous reports demonstrating a similar
pattern of expression of TNF-x mRNA (Miles et al., 1992). TNF-a localisation was seen to be heterogeneous within
tumours, which could reflect the existence of TNF-x 'hot
spots'. This phenomenon may generate TNF-resistant clones
of neoplastic cells in certain areas owing to exposure to low
doses of TNF-a for sufficiently prolonged periods. Interest-
ingly, TNF-c-resistant cells are resistant to certain
chemotherapeutic drugs in vitro (Wright et al., 1992). TNF-R p55 was expressed by neoplastic cells in 75% of
tumours. This is particularly interesting in view of our recent
finding that this type of TNF-R mediates the cytostatic/ cytotoxic effect of TNF-x on breast cancer cell lines in vitro
(L. Pusztai, C.E. Lewis & J. O'D. McGee, unpublished observations). A significant correlation between the expres- sion of TNF-R p55 by blood vessels and the amount of
leucocyte infiltration present in tumours suggests that the292 L. PUSZTAI el al.
expression of this receptor by vascular endothelial cells may
facilitate migration of immunocompetent cells into the
tumour site. Such an effect is anticipated by the in vitro
activities of TNF-a (Gamble et al., 1992). Alternatively, this
expression pattern may indicate an endothelial reaction to
the presence of mononuclear inflammatory cells or neoplastic
cells infiltrating the tissue.
Activated, but not unstimulated, T cells express TNF
receptors both in vitro and in vivo (Ware et al., 1991). The
lack ofexpression ofTNF-x and its receptors by the majority
of tumour-infiltrating mononuclear cells may reflect the
relative absence of activated leucocytes in breast carcinomas.
Indeed, other leucocyte activation markers (IL-2 receptor,
IgE receptor, transferrin receptor) were also expressed by
only a few tumour-infiltrating leucocytes in these tumours (L.
Pusztai, C.E. Lewis & J.O'D. McGee, unpublished observa-
tions). However, it should be noted that such immuno-
phenotypic activation markers are characterised in in vitro
assays and may not reflect the functional status of tissue
leucocytes.
It is difficult to assess the possible biological significance, if
any, of the aforementioned expression and cellular distribu-
tion of TNF-x and its receptors in breast tumours, especially
since it could not be correlated with the proliferative and
metastatic potential of the neoplastic cells, the angiogenic
activity and degree of leucocyte infiltration of tumours, and
routine prognostic indicators such as tumour size and grade.
However, the small number of cases involved in this
preliminary study means that a weak correlation between the
presence of TNF-x or TNF receptors and the biological
behaviour of the tumours may not have been detectable. It is
also possible that TNF-x and its receptors play a more
important role in the progression of early (preclinical) breast
tumours rather than those used in this study, which were
clinically manifest and, therefore, biologically quite
advanced.
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